|Over a week ago|
Abcam participates in a conference call with SVB Leerink » 09:0703/3003/30/21
Conference call with CEO…
Conference call with CEO Hirzel will be held on March 30 at 9 am hosted by SVB Leerink.
Abcam price target raised to 1,300 GBp from 1,180 GBp at Berenberg » 14:2503/1203/12/21
Berenberg analyst Xian…
Berenberg analyst Xian Deng raised the firm's price target on Abcam to 1,300 GBp from 1,180 GBp and keeps a Hold rating on the shares.
|Over a month ago|
Abcam price target lowered to 1,300 GBp from 1,400 GBp at JPMorgan » 13:1503/0903/09/21
JPMorgan analyst James…
JPMorgan analyst James Gordon lowered the firm's price target on Abcam to 1,300 GBp from 1,400 GBp and keeps a Neutral rating on the shares.
Abcam price target lowered to 1,640 GBp from 1,750 GBp at RBC Capital » 13:0303/0903/09/21
RBC Capital analyst…
RBC Capital analyst Charles Weston lowered the firm's price target on Abcam to 1,640 GBp from 1,750 GBp and keeps an Outperform rating on the shares.
Abcam says implementation of strategy remains within expectations » 07:3003/0803/08/21
The company said,…
The company said, "Fundamental drivers of the life science research market remain attractive with stable public funding and an increasing emphasis on proteomics and clinically relevant biologics. Implementation of Abcam's strategy remains within the Board's expectations of timing, costs, and milestones. We remain confident in realizing growth from these investments and generating an attractive return on capital employed as we gain operational leverage, normalize capital investment, and generate more of our own product at higher gross margins . COVID-19 pandemic controls continue to constrain researcher access to approximately 50% of labs globally. These constraints are limiting scientific discovery capacity and we observe demand in those labs well below historic levels . With over 15 months of operational experience through the pandemic, we remain cautious in our assessment of when laboratory activity and demand will return to full strength .We are updating our long-term outlook to reflect a broader range of potential outcomes than originally outlined in November 2019, with a range of revenue outcomes for the end of calendar 2024 of GBP 425 - 500m. We expect to provide further information when laboratory activity and demand return to normal levels."
Abcam announces change of accounting reference date » 07:2903/0803/08/21
Before the end of this…
Before the end of this fiscal year, the Board intends to change the Company's accounting reference date. The Board has undertaken a review of the appropriate year end for the Company and has decided that this year would be the right time to move the fiscal year end from 30 June to 31 December. Following this change, the Company's near-term reporting calendar will be as follows: Unaudited results for the six- and twelve-month periods to 30 June 2021 to be announced in September 2021; Audited results for the twelve and 18-month periods to 31 December 2021 to be announced in March 2022; Publication of the 2021 annual report and accounts expected before the end of April 2022. Furthermore, assuming the change in accounting reference date is implemented as expected, the Company plans to hold future AGMs in the second calendar quarter of each year, and will hold a general meeting in the summer to review necessary authorities that would otherwise expire before the next AGM.
Abcam reports 1H adjusted EPS 8.1p vs. 13p last year » 07:2803/0803/08/21
Reports 1H revenue…
Reports 1H revenue GBP147.5M vs. GBP138.2M last year. Commenting on the first half performance, Alan Hirzel, Abcam's CEO, said: "We delivered over 8% revenue growth at constant exchange rates in the first half year as we started to see more activity in our customers' labs. Whilst we haven't yet observed a return to normal demand, we are encouraged by the 25% growth in our in-house products and the long-term outlook for Abcam. We remain confident in our growth strategy and are committed to investing in innovation and building an increasingly strong and sustainable global business."
Abcam upgraded to Outperform from Sector Perform at RBC Capital » 05:3601/1201/12/21
RBC Capital analyst…
RBC Capital analyst Charles Weston upgraded Abcam to Outperform from Sector Perform with a 1,750 GBp price target.
Abcam to host conference call » 09:0001/1101/11/21
Conference call to…
Conference call to provide trading update will be held on January 11 at 9 am. Webcast Link
Abcam sees 1H revenue GBP147.5M vs. GBP138.2M last year » 08:2601/1101/11/21
Abcam announces the…
Abcam announces the following unaudited trading update ahead of reporting its results on 8 March 2021 for the six months ended 31 December 2020. The company said, "Overall, we expect to report total first half revenue of GBP147.5M , representing growth of 8.3% on a constant currency basis and 6.7% on a reported basis. In-house products represented over 55% of total revenue and grew by over 25%. On a constant currency basis, catalogue revenue, representing 95% of the total, grew approximately 8.0% in the half whilst CP&L revenue grew double-digit. We grew high single- to double-digits in all regions other than the Americas where customer laboratory activity has been more constrained due to COVID-19. Gross margin is expected to be in line with board expectations at approximately 70.5%, ahead of the first half of last year. We expect to report an adjusted operating margin for the first half of approximately 16%. We were also pleased to complete in October our US equity listing of American Depositary Shares on The Nasdaq Global Select Market in October."